Clinical Trial

sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 7, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS). Additionally, to characterize the safety and toxicity profile of the study treatment as measured by the adverse event rates.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-04-15; most recent amendment 2026-01-05.
Status change: Not Yet Recruiting → Recruiting 2022-07-24
Trial Details
NCT Number NCT05332002
Lead Sponsor Rutgers, The State University of New Jersey
Conditions Gastro-Intestinal Cancer
Enrollment 38 participants
Start Date 2022-07-13
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-07